株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アテローム性動脈硬化症:パイプライン製品の分析

Atherosclerosis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232865
出版日 ページ情報 英文 252 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
アテローム性動脈硬化症:パイプライン製品の分析 Atherosclerosis - Pipeline Review, H2 2016
出版日: 2016年11月09日 ページ情報: 英文 252 Pages
概要

アテローム性動脈硬化症は、プラークが蓄積することで動脈が肥厚し硬化する疾患です。血流を阻害し、深刻な心血管障害を引き起こします。症状は胸痛、四肢または動脈が閉塞した箇所の痛み、息切れ、疲労感、意識障害、血流不足による足の筋力低下などです。

当レポートでは、アテローム性動脈硬化症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

アテローム性動脈硬化症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

アテローム性動脈硬化症:企業で開発中の治療薬

アテローム性動脈硬化症:大学/機関で研究中の治療薬

アテローム性動脈硬化症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

アテローム性動脈硬化症:企業で開発中の製品

アテローム性動脈硬化症:大学/機関で研究中の製品

アテローム性動脈硬化症の治療薬開発に従事している企業

  • Ache Laboratorios Farmaceuticos S/A
  • advanceCor GmbH
  • AFFiRiS AG
  • Amgen Inc.
  • Arisaph Pharmaceuticals, Inc.
  • Artery Therapeutics, Inc.
  • AstraZeneca Plc
  • Athera Biotechnologies AB
  • AtheroNova Inc.
  • Bayer AG
  • Campus Technologies Freiburg GmbH
  • Cardax Pharmaceuticals, Inc.
  • Cerenis Therapeutics Holding SA
  • ChemoCentryx, Inc.
  • CohBar, Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • 第一三共
  • DoNatur GmbH
  • Dybly AG
  • Exicure, Inc.
  • GenKyoTex S.A.
  • Jenrin Discovery, Inc.
  • Johnson & Johnson
  • KineMed, Inc.
  • 興和
  • La Jolla Pharmaceutical Company
  • Lead Discovery Center GmbH
  • Merck & Co., Inc.
  • MI.TO. Technology S.r.L.
  • Omeros Corporation
  • OPKO Health, Inc.
  • 大塚ホールディングス
  • Resverlogix Corp.
  • The Medicines Company
  • Therapix Biosciences Ltd
  • Tolerys SA
  • Vascular Biogenics Ltd.
  • Vericel Corporation
  • Vitae Pharmaceuticals, Inc.
  • XBiotech USA, Inc.

アテローム性動脈硬化症:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

アテローム性動脈硬化症:最近のパイプライン動向

アテローム性動脈硬化症:休止中のプロジェクト

アテローム性動脈硬化症:開発が中止された製品

アテローム性動脈硬化症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8629IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atherosclerosis - Pipeline Review, H2 2016, provides an overview of the Atherosclerosis (Cardiovascular) pipeline landscape.

Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive build up of plaque around the artery wall. The disease disrupts the flow of blood around the body, posing serious cardiovascular complications. Symptoms of atherosclerosis are chest pain (angina), pain in the leg, arm, and anywhere else that an artery is blocked, shortness of breath, fatigue, confusion (if the blockage affects circulation to the brain) and muscle weakness in the legs from lack of circulation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atherosclerosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Atherosclerosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atherosclerosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 5, 43 and 14 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 25 and 4 molecules, respectively.Atherosclerosis.

Atherosclerosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atherosclerosis (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Atherosclerosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atherosclerosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atherosclerosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atherosclerosis (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atherosclerosis (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atherosclerosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Atherosclerosis Overview
  • Therapeutics Development
  • Atherosclerosis - Therapeutics under Development by Companies
  • Atherosclerosis - Therapeutics under Investigation by Universities/Institutes
  • Atherosclerosis - Pipeline Products Glance
  • Atherosclerosis - Products under Development by Companies
  • Atherosclerosis - Products under Investigation by Universities/Institutes
  • Atherosclerosis - Companies Involved in Therapeutics Development
  • Atherosclerosis - Therapeutics Assessment
  • Drug Profiles
  • Atherosclerosis - Dormant Projects
  • Atherosclerosis - Discontinued Products
  • Atherosclerosis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Atherosclerosis, H2 2016
  • Number of Products under Development for Atherosclerosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Atherosclerosis - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016
  • Atherosclerosis - Pipeline by advanceCor GmbH, H2 2016
  • Atherosclerosis - Pipeline by AFFiRiS AG, H2 2016
  • Atherosclerosis - Pipeline by Akcea Therapeutics Inc, H2 2016
  • Atherosclerosis - Pipeline by Amgen Inc., H2 2016
  • Atherosclerosis - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016
  • Atherosclerosis - Pipeline by ARMO Biosciences, Inc., H2 2016
  • Atherosclerosis - Pipeline by Artery Therapeutics, Inc., H2 2016
  • Atherosclerosis - Pipeline by Athera Biotechnologies AB, H2 2016
  • Atherosclerosis - Pipeline by Cardax, Inc., H2 2016
  • Atherosclerosis - Pipeline by Cerenis Therapeutics Holding SA, H2 2016
  • Atherosclerosis - Pipeline by ChemoCentryx, Inc., H2 2016
  • Atherosclerosis - Pipeline by CohBar, Inc., H2 2016
  • Atherosclerosis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
  • Atherosclerosis - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Atherosclerosis - Pipeline by DoNatur GmbH, H2 2016
  • Atherosclerosis - Pipeline by Dybly AG, H2 2016
  • Atherosclerosis - Pipeline by GenKyoTex S.A., H2 2016
  • Atherosclerosis - Pipeline by HitGen LTD, H2 2016
  • Atherosclerosis - Pipeline by Jenrin Discovery, Inc., H2 2016
  • Atherosclerosis - Pipeline by Kang Stem Biotech Co., Ltd., H2 2016
  • Atherosclerosis - Pipeline by KineMed, Inc., H2 2016
  • Atherosclerosis - Pipeline by Kowa Company, Ltd., H2 2016
  • Atherosclerosis - Pipeline by La Jolla Pharmaceutical Company, H2 2016
  • Atherosclerosis - Pipeline by Lead Discovery Center GmbH, H2 2016
  • Atherosclerosis - Pipeline by LipimetiX Development Inc, H2 2016
  • Atherosclerosis - Pipeline by Merck & Co., Inc., H2 2016
  • Atherosclerosis - Pipeline by Omeros Corporation, H2 2016
  • Atherosclerosis - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Atherosclerosis - Pipeline by Resverlogix Corp., H2 2016
  • Atherosclerosis - Pipeline by The Medicines Company, H2 2016
  • Atherosclerosis - Pipeline by Therapix Biosciences Ltd., H2 2016
  • Atherosclerosis - Pipeline by Tolerys SA, H2 2016
  • Atherosclerosis - Pipeline by Unity Biotechnology, Inc., H2 2016
  • Atherosclerosis - Pipeline by Vascular Biogenics Ltd., H2 2016
  • Atherosclerosis - Pipeline by Vericel Corporation, H2 2016
  • Atherosclerosis - Pipeline by Vicore Pharma AB, H2 2016
  • Atherosclerosis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2016
  • Atherosclerosis - Pipeline by XBiotech Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Atherosclerosis - Dormant Projects, H2 2016
  • Atherosclerosis - Dormant Projects (Contd..1), H2 2016
  • Atherosclerosis - Dormant Projects (Contd..2), H2 2016
  • Atherosclerosis - Dormant Projects (Contd..3), H2 2016
  • Atherosclerosis - Dormant Projects (Contd..4), H2 2016
  • Atherosclerosis - Dormant Projects (Contd..5), H2 2016
  • Atherosclerosis - Dormant Projects (Contd..6), H2 2016
  • Atherosclerosis - Dormant Projects (Contd..7), H2 2016
  • Atherosclerosis - Dormant Projects (Contd..8), H2 2016
  • Atherosclerosis - Dormant Projects (Contd..9), H2 2016
  • Atherosclerosis - Dormant Projects (Contd..10), H2 2016
  • Atherosclerosis - Dormant Projects (Contd..11), H2 2016
  • Atherosclerosis - Discontinued Products, H2 2016
  • Atherosclerosis - Discontinued Products (Contd..1), H2 2016
  • Atherosclerosis - Discontinued Products (Contd..2), H2 2016

List of Figures

  • Number of Products under Development for Atherosclerosis, H2 2016
  • Number of Products under Development for Atherosclerosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top